P28482 (MK01_HUMAN) Homo sapiens (Human)

Mitogen-activated protein kinase 1 UniProtKBAFDB90v4InterProSTRINGInteractive Modelling

360 aa; Sequence (Fasta) ; (Isoform 2); 33 identical sequences

Available Structures

145 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Phosphorylated ERK2 in complex with ORF45
7opm
 Heteromer
F5HDE4; 		1-360
1×08G; 3×GOL;
Assess
Heterodimeric structure of ERK2 and RSK1
4nif
 Heteromer
Q15418; 		9-360
2×ANP; 3×SO4; 2×NA;
Assess
Crystal structure of human ERK2 complexed with a MAPK docking peptide
4h3q
 Heteromer
P36507; 		9-360
1×ANP;
Assess
Phospho-ERK2 bound to bivalent inhibitor SBP3
5v62
 Heteromer
Q15418; 		10-360
5×GOL; 1×FRZ; 1×AKS;
Assess
Crystal structure of human ERK2 complexed with a MAPK docking peptide
2y9q
 Heteromer
Q9BUB5; 		9-358
1×ANP;
Assess
Structure of Non-Phosphorylated ERK2 bound to the PEA-15 Death Effector Domain
4iz7
 Heteromer
Q9Z297; 		11-360
1×NA;
Assess
Phospho-ERK2 bound to bivalent inhibitor SBP2
5v61
 Heteromer
Q15418; 		10-359
3×GOL; 1×FRZ; 1×90A;
Assess
Crystal structure of human ERK2 complexed with a MAPK docking peptide
4h3p
 Heteromer
Q15418; 		11-359
1×ANP;
Assess
Crystal structure of human ERK2 complexed with a MAPK docking peptide
3tei
 Heteromer
Q15418; 		10-358
1×ANP;
Assess
Crystal structure of ERK2 complexed with allosteric and ATP-competitive inhibitors.
5ax3
 Heteromer
P40763; 		10-358
1×5ID;
Assess
Structure of Dually Phosphorylated ERK2 bound to the PEA-15 Death Effector Domain
4iza
 Heteromer
Q15121; 		11-358
Assess
Structure of the complex between ERK2 phosphomimetic mutant and PEA-15
4iz5
 Heteromer
Q15121; 		11-357
1×ADP; 4×SO4;
Assess
Crystal structure of HePTP in complex with a dually phosphorylated Erk2 peptide mimetic
3d44
 Heteromer
P35236; 		185-188
3×CL; 1×GOL;
Assess
Crystal structure of HePTP in complex with a monophosphorylated Erk2 peptide
3d42
 Heteromer
P35236; 		185-188
1×TAR; 1×GOL;
Assess
Complex of ERK2 with norathyriol
3sa0
monomer4-360
1×NRA; 1×SO4;
Assess
Complex of ERK2 with caffeic acid
4n0s
monomer6-357
1×DHC; 3×SO4; 1×PEG; 2×DMS;
Assess
Co-crystal structure of phosphorylated ERK2 in complex with ERK1/2 inhibitor #16
8u8j
monomer7-358
1×WAL;
Assess
Complex of ERK2 with catechol
4zxt
monomer7-357
1×CAQ; 3×SO4; 2×NH4;
Assess
Crystal structure of ERK2 with an allosteric inhibitor 3
7xc1
monomer10-360
1×5ID; 1×EPE; 2×GOL; 1×B8Z; 1×SO4;
Assess
Crystal structure of ERK2 bound to (S)-4-(2-(2-chlorophenylamino)-5-methylpyrimidin-4-yl)-N-(2-hydr…
3i60
monomer8-358
3×SO4; 1×E86;
Assess
ERK2 mini-fragment binding
6qa3
monomer8-357
1×SO4; 2×PZO;
Assess
Crystal Structure of ERK2 in complex with compound 22
5k4i
monomer9-358
1×6QB; 2×EDO;
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…
6g9d
monomer8-357
5×SO4; 1×ER8;
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…
6g91
monomer8-357
2×SO4; 1×EQW;
Assess
Erk2 signalling protein
6gjb
monomer8-357
5×SO4; 1×F0H;
Assess
ERK2 mini-fragment binding
6q7k
monomer8-357
1×SO4; 1×2AI;
Assess
ERK2 complexed with a N-H tetrahydroazaindazole
5buj
monomer9-358
1×4VB;
Assess
Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase
5bvd
monomer9-358
1×4VF; 5×SO4;
Assess
Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase
5bvf
monomer9-358
1×4VJ; 5×SO4;
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…
6g9a
monomer8-357
3×SO4; 1×ESQ;
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…
6g9j
monomer8-357
2×SO4; 1×ERK;
Assess
Crystal structure of ERK2 with an allosteric inhibitor 2
7x4u
monomer10-359
1×5ID; 1×8DK; 3×GOL; 1×BTB; 1×SO4;
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…
6g92
monomer8-357
3×SO4; 1×ERZ;
Assess
Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase
5bve
monomer9-358
1×4VG; 4×SO4;
Assess
Crystal Structure of the ERK2 complexed with E63
4fv8
monomer8-357
1×E63; 4×SO4; 1×EDO;
Assess
Crystal structure of human ERK2 complexed with a MAPK docking peptide
4fmq
monomer9-358
1×ANP;
Assess
Crystal Structure of the ERK2 complexed with E71
4fv9
monomer8-357
1×E71; 5×SO4; 1×EDO;
Assess
Crystal structure of ERK2 bound to (S)-N-(2-hydroxy-1-phenylethyl)-4-(5-methyl-2-(phenylamino)pyrim…
3i5z
monomer8-357
4×SO4; 1×Z48;
Assess
Crystal structure of ERK2 with an allosteric inhibitor
7w5o
monomer11-360
1×5ID; 3×MLA; 2×SIN; 1×NA; 1×EPE;
Assess
Crystal structure of human ERK2 complexed with a pyrazolopyridazine derivative
1wzy
monomer8-357
1×F29;
Assess
The structure of ERK2 in complex with a small molecule inhibitor
1tvo
monomer8-357
1×FRZ;
Assess
Structure of human ERK2 in complex with SCH772984 revealing a novel inhibitor-induced binding pocket
4qta
monomer10-358
8×EDO; 2×SO4; 1×38Z;
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…
6gdm
monomer8-356
2×SO4; 1×DMS; 1×F3Z;
Assess
Co-crystal structure of phosphorylated ERK2 in complex with ERK1/2 inhibitor #8
8u8k
monomer10-358
1×W8U;
Assess
Phospho-ERK2 bound to AMP-PCP
5v60
monomer10-358
1×ACP; 6×GOL; 2×MG;
Assess
Crystal Structure of ERKs in complex with 5-chlorobenzo[d]oxazol-2-amine
4qp2
monomer12-360
1×36R; 1×IMD;
Assess
Crystal Structure of the ERK2 complexed with EK9
4fv5
monomer9-357
1×EK9; 5×SO4; 1×EDO;
Assess
Crystal structure of human ERK2 mutant (G37C)
7e75
monomer10-358
Assess
Crystal Structure of the ERK2 complexed with EK7
4fv4
monomer9-357
1×EK7; 3×SO4; 1×GOL;
Assess
Crystal Structure of the ERK2 complexed with E57
4fv6
monomer9-357
1×E57; 3×SO4; 1×EDO;
Assess
Crystal structure of ERK2 in complex with an inhibitor 14K
4xj0
monomer12-360
1×41B;
Assess
Crystal Structure of ERK2 in complex with (S)-2-((9H-purin-6-yl)amino)-3-phenylpropan-1-ol
4qp3
monomer12-360
1×36Q;
Assess
Crystal structure of ERK2 in complex with N-cyclohexyl-9H-purin-6-amine
4qp1
monomer12-360
1×EMU; 1×IMD;
Assess
phosphorylated ERK2 with AMP-PNP
6opg
monomer10-358
1×ANP; 2×MG;
Assess
Crystal Structure of ERK2 in complex with 5H-pyrrolo[2,3-b]pyrazine
4qp6
monomer12-360
1×36N; 1×IMD;
Assess
Structure of ERK2 in complex with VTX-11e, 4-{2-[(2-CHLORO-4-FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-…
4qte
monomer11-358
22×EDO; 5×SO4; 2×CL; 1×390;
Assess
ERK2 mini-fragment binding
6qa1
monomer11-358
1×SO4; 7×HVK;
Assess
Erk2 signalling protein
6gjd
monomer10-357
7×SO4; 2×DMS; 1×GOL; 1×F0E;
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…
6gdq
monomer10-357
5×SO4; 1×DMS; 1×EVK;
Assess
Crystal Structure of the ERK2 complexed with E94
4fv7
monomer11-358
1×E94; 3×SO4; 3×EDO; 1×GOL;
Assess
Human Erk2 with an Erk1/2 inhibitor
5nhh
monomer11-358
3×SO4; 1×8XH;
Assess
Crystal Structure of the ERK2
4g6n
monomer11-358
1×EK0; 2×SO4;
Assess
Crystal Structure of the ERK2 complexed with EK2
4fuy
monomer11-358
1×EK2; 2×SO4; 1×EDO;
Assess
Crystal Structure of the ERK2 complexed with EK3
4fv0
monomer11-358
1×EK3; 8×EDO; 2×GOL;
Assess
ERK2 complexed with 2-pyridiyl tetrahydroazaindazole
5bui
monomer11-358
1×NI; 1×4V9;
Assess
phosphorylated ERK2 with GDC-0994
6oph
monomer11-358
1×6QB;
Assess
ERK2 complexed with N-benzylpyridone tetrahydroazaindazole
5bue
monomer11-358
1×4V8; 1×NI;
Assess
Specific covalent inhibitor of ERK2
8aoj
monomer10-356
2×SO4; 3×EDO; 1×DMS; 1×N8L;
Assess
ERK2 mini-fragment binding
6qal
monomer11-357
4×SO4; 2×HV2;
Assess
ERK2 mini-fragment binding
6qah
monomer11-357
1×SO4; 2×HVB;
Assess
ERK2 mini-fragment binding
6qaq
monomer11-357
4×SO4; 2×HVQ;
Assess
ERK2 mini-fragment binding
6qa4
monomer11-357
1×SO4; 4×HRZ;
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…
6g93
monomer11-357
5×SO4; 1×EU2;
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…
6g9h
monomer11-357
4×SO4; 1×ERW;
Assess
The structure of ERK2 in complex with dual inhibitor ASTX029
7auv
monomer11-357
3×SO4; 1×DMS; 1×RYW;
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…
6g8x
monomer11-357
2×SO4; 2×EQT;
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…
6g9n
monomer11-357
6×SO4; 1×ESN;
Assess
Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activi…
7nr5
monomer11-357
4×SO4; 1×UOH;
Assess
Specific covalent inhibitor of ERK2
8ao3
monomer11-357
2×SO4; 1×NYX;
Assess
In-Gel Activity-Based Protein Profiling of a Clickable Covalent Erk 1/2 Inhibitor
5lcj
monomer11-357
1×6TS; 2×SO4;
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…
6ge0
monomer11-357
2×SO4; 3×DMS; 1×EVQ;
Assess
Specific covalent inhibitor (5) of ERK2
8ao4
monomer11-357
1×SO4; 1×EDO; 1×PEG; 1×N8U;
Assess
ERK2 mini-fragment binding
6qaw
monomer11-357
1×SO4; 1×HVE;
Assess
A Clickable Covalent ERK 1/2 Inhibitor
5lck
monomer11-357
4×SO4; 1×6TT;
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…
6g97
monomer11-357
6×SO4; 1×EQZ;
Assess
WT ERK2 with compound 2507-8
6nbs
monomer10-356
1×SO4; 1×GOL; 1×KJ7; 1×KJ4;
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…
6g9k
monomer11-357
3×SO4; 1×ESK;
Assess
Crystal Structure of the ERK2 complexed with EK5
4fv2
monomer11-357
1×EK5; 2×SO4; 3×GOL; 5×EDO;
Assess
Crystal structure of ERK2 covalently bound to SM1-71
6g54
monomer10-356
2×SO4; 1×6H3; 13×EDO; 1×CL;
Assess
ERK2 mini-fragment binding
6qag
monomer11-357
3×SO4; 2×HUH;
Assess
Crystal Structure of the ERK2 complexed with E75
4fux
monomer11-357
1×E75; 2×SO4; 1×EDO;
Assess
Crystal Structure of the ERK2 complexed with EK6
4fv3
monomer11-357
1×EK6; 3×SO4; 3×EDO;
Assess
A multiconformer ligand model of EK6 bound to ERK2
6dmg
monomer11-357
3×SO4; 3×EDO; 1×EK6;
Assess
Crystal Structure of the ERK2
4g6o
monomer11-357
1×E28; 1×SO4; 4×EDO;
Assess
Crystal structure of human ERK2 mutant (Y36H)
7e73
monomer11-357
1×SO4;
Assess
phosphorylated ERK2 with SCH-CPD336
6opi
monomer10-356
1×N0V;
Assess
The structure of ERK2 in complex with FR148083
3w55
monomer11-357
1×1FM;
Assess
Specific covalent inhibitor(18) of ERK2
8aoh
monomer11-356
1×SO4; 1×EDO; 1×DMS; 1×PEG; 2×N96;
Assess
ERK2 mini-fragment binding
6q7t
monomer11-356
1×SO4; 2×HOW;
Assess
Specific covalent inhibitor(19) of ERK2
8aoi
monomer11-356
2×SO4; 2×EDO; 2×NX0;
Assess
Non-specific covalent inhibitor(17) of ERK2
8aog
monomer11-356
1×SO4; 2×EDO; 3×N29;
Assess
Specific covalent inhibitor (8) of ERK2
8ao7
monomer11-356
2×SO4; 2×EDO; 1×N3X;
Assess
Specific covalent inhibitor(16) of ERK2
8aof
monomer11-356
1×SO4; 2×EDO; 1×N4U;
Assess
Covalent and non-covalent inhibitor of ERK2 (two sites)
8aoa
monomer11-356
1×SO4; 3×EDO; 1×DMS; 1×N83; 1×OZU;
Assess
Specific covalent inhibitor of ERK2
8aoc
monomer11-356
1×SO4; 2×EDO; 1×N3O;
Assess
Specific covalent inhibitor(14) of ERK2
8aod
monomer11-356
2×SO4; 1×EDO; 1×NY0; 1×NYI;
Assess
Specific covalent inhibitor(10) of ERK2
8ao9
monomer11-356
1×SO4; 2×EDO; 2×PEG; 1×N4F;
Assess
Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activi…
7nr8
monomer11-356
3×SO4; 3×DMS; 1×EDO; 1×UOE;
Assess
Specific covalent inhibitor(15) of ERK2
8aoe
monomer11-356
1×SO4; 2×EDO; 1×N6U;
Assess
Specific covalent inhibitor(9) of ERK2
8ao8
monomer11-356
1×SO4; 2×EDO; 1×N5U;
Assess
ERK2 mini-fragment binding
6q7s
monomer11-356
1×SO4; 2×IPH;
Assess
Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activi…
7nqw
monomer11-356
2×SO4; 2×DMS; 1×UNW;
Assess
electrophilic inhibitor (7) of ERK2
8ao6
monomer11-356
1×SO4; 1×PEG; 3×EDO; 1×N9F;
Assess
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phos…
6g9m
monomer11-356
3×SO4; 1×ESW;
Assess
Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activi…
7nr3
monomer11-356
2×SO4; 1×UO5;
Assess
Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activi…
7nqq
monomer11-356
4×SO4; 1×DMS; 1×UMN;
Assess
Crystal Structure of the ERK2 complexed with EK4
4fv1
monomer11-356
1×EK4; 1×GOL; 1×SO4; 4×EDO;
Assess
Crystal Structure of ERK2 in complex with 2-(1H-pyrazol-4-yl)-7-(pyridin-3-yl)-5H-pyrrolo[2,3-b]pyr…
4qp8
monomer12-357
1×362;
Assess
Crystal Structure of ERK2 in complex with 7-(1-benzyl-1H-pyrazol-4-yl)-2-(pyridin-4-yl)-5H-pyrrolo[…
4qpa
monomer12-357
1×35W;
Assess
Human ERK2 in complex with an inhibitor
4zzn
monomer11-355
1×SO4; 1×CQ8;
Assess
Human ERK2 in complex with an irreversible inhibitor
4zzo
monomer11-355
1×SO4; 1×CQ3;
Assess
Specific covalent inhibitor (3) of ERK2
8ao2
monomer13-357
1×SO4; 1×EDO; 1×NXI;
Assess
Human ERK2 in complex with an irreversible inhibitor
4zzm
monomer11-355
1×SO4; 1×CQ6;
Assess
Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activi…
7nr9
monomer11-355
1×SO4; 1×UOW;
Assess
Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine Inhibitors of Erk2
4o6e
monomer13-357
1×2SH;
Assess
Human Erk2 with an Erk1/2 inhibitor
5nhp
monomer11-355
2×SO4; 1×8XK;
Assess
STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MA…
1pme
monomer16-360
1×SO4; 1×SB2;
Assess
Human Erk2 with an Erk1/2 inhibitor
5nhv
monomer11-355
1×SO4; 1×8QB;
Assess
Crystal Structure of ERK2 in complex with 7-(1-propyl-1H-pyrazol-4-yl)-2-(pyridin-4-yl)-5H-pyrrolo[…
4qp9
monomer13-357
1×35X;
Assess
Human Erk2 with an Erk1/2 inhibitor
5nhl
monomer11-355
1×SO4; 1×8XB;
Assess
Human Erk2 with an Erk1/2 inhibitor
5nhj
monomer11-355
2×SO4; 1×8XE;
Assess
Crystal Structure of ERK2 in complex with N-cyclohexyl-9H-purin-6-amine
4qp4
monomer13-357
1×36O;
Assess
Human Erk2 with an Erk1/2 inhibitor
5nho
monomer11-355
1×SO4; 1×8XN;
Assess
Crystal Structure of ERK2 in complex with 2-(1H-pyrazol-4-yl)-5H-pyrrolo[2,3-b]pyrazine
4qp7
monomer13-357
1×363;
Assess
Human Erk2 with an Erk1/2 inhibitor
5ngu
monomer11-355
2×SO4; 1×8X2;
Assess
Crystal structure of ERK2 G169D mutant
6d5y
monomer13-357
Assess
Human Erk2 with an Erk1/2 inhibitor
5nhf
monomer12-355
1×SO4; 1×8X5;
Assess
Crystal structure of ERK2 in complex with (S)-N-(1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl)-4-(4-(…
2ojj
monomer15-358
1×SO4; 1×82A;
Assess
Crystal structure of ERK2 in complex with N-benzyl-4-(4-(3-chlorophenyl)-1H-pyrazol-3-yl)-1H-pyrrol…
2oji
monomer15-358
1×SO4; 1×33A;
Assess
Complex of ERK2 with 5,7-dihydroxychromone
5wp1
monomer15-357
1×B7S; 1×SO4; 1×BEZ;
Assess
Specific covalent inhibitor (6) of ERK2
8ao5
monomer15-356
2×SO4; 1×EPE; 1×N6K;
Assess
HUMAN ERK2 WITH ERK1/2 INHIBITOR, AZD0364.
6slg
monomer18-356
1×LHZ; 2×SO4; 4×EDO;
Assess
Specific covalent inhibitor(12) of ERK2
8aob
monomer18-356
1×SO4; 1×PEG; 1×NB3;
Assess
Inhibitor of ERK2
6rq4
monomer19-357
1×SO4; 1×KE8;
Assess
Crystal structure of ERK2 in complex with N,N-dimethyl-4-(4-phenyl-1H-pyrazol-3-yl)-1H-pyrrole-2-ca…
2ojg
monomer19-357
1×SO4; 1×19A;
Assess

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
4qtb.1.Amonomer0.8912-357
1×38Z;87.90
Assess

1 SWISS-MODEL model built on isoform sequence

TemplateIsoformOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 24qp3.1.Amonomer0.8212-316
1×36Q;99.05
Assess